Bicycle Therapeutics plc
As of Oct 22, 2026, Bicycle Therapeutics is in Stage 4, the downtrend phase, now in week 5 (since Sep 18, 2026). It closed at $3.64, 58.4% below its 52-week high and below its 200-day average, which is falling.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BCYC early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BCYC among Biotechnology375th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …375 | BCYC | Stage 4 · wk 5 | 21 | +1.1% |
Bicycle Therapeutics: quick answers
What stage is Bicycle Therapeutics in?
As of Oct 22, 2026, Bicycle Therapeutics (BCYC) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 18, 2026 and is in week 5. What the four stages mean
Is Bicycle Therapeutics in an uptrend?
No. Bicycle Therapeutics is in a Stage 4 downtrend. It trades 21.7% below its 200-day average, which is falling.
How far is Bicycle Therapeutics from its 52-week high?
Bicycle Therapeutics closed at $3.64 on Oct 22, 2026, 58.4% below its 52-week high of $8.76. Its 52-week low is $3.38.
How has Bicycle Therapeutics performed over the past year?
As of Oct 22, 2026, Bicycle Therapeutics is down 56.1% over the past year and down 45.5% so far in 2026.
Which sector and industry is Bicycle Therapeutics in?
Bicycle Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.